Alnylam Pharmaceuticals | ALNY - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amgen USD 657M 4M 2026-03
Arrowhead Research USD 22.5M 811K 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Incyte USD 569K 13K 2026-03
Ionis Pharmaceuticals USD 17M 1000K 2026-03
Moderna USD 11.49B 36B 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 281M 8M 2025-09
PTC Therapeutics USD 2.87B 2.82B 2026-03
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR -25M 99.78M 2025-12
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
Takeda JPY 43.65B 79.98B 2026-03
Tectonic Therapeutic USD 246.58M 246.56M 2026-03
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xencor USD 4.7M 2.65M 2026-03